Vertex Pharmaceuticals Financials
| VRTX34 Stock | BRL 712.80 8.77 1.22% |
Vertex |
Please note, the presentation of Vertex Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vertex Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Vertex Pharmaceuticals' management manipulating its earnings.
Vertex Pharmaceuticals Stock Summary
Vertex Pharmaceuticals competes with British American, Nordon Indstrias, United States, and METISA Metalrgica. Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. VERTEX PHARMDRN operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 3400 people.| Instrument | Brazil Stock View All |
| Exchange | Sao Paulo Exchange |
| Business Address | 50 Northern Avenue, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.vrtx.com |
| Phone | 617 341 6100 |
| Currency | BRL - Brazilian Real |
You should never invest in Vertex Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Vertex Stock, because this is throwing your money away. Analyzing the key information contained in Vertex Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Vertex Pharmaceuticals Key Financial Ratios
Vertex Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Vertex Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Vertex Pharmaceuticals over time and compare it to other companies across industries.Vertex Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Vertex Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Vertex Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vertex Pharmaceuticals competition to find correlations between indicators driving Vertex Pharmaceuticals's intrinsic value. More Info.Vertex Pharmaceuticals Incorporated is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.63 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Vertex Pharmaceuticals Incorporated is roughly 1.60 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Vertex Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Vertex Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Vertex Pharmaceuticals Systematic Risk
Vertex Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Vertex Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-one with a total number of output elements of fourty. The Beta measures systematic risk based on how returns on Vertex Pharmaceuticals correlated with the market. If Beta is less than 0 Vertex Pharmaceuticals generally moves in the opposite direction as compared to the market. If Vertex Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Vertex Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Vertex Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Vertex Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Vertex Pharmaceuticals March 30, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Vertex Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Vertex Pharmaceuticals Incorporated. We use our internally-developed statistical techniques to arrive at the intrinsic value of Vertex Pharmaceuticals Incorporated based on widely used predictive technical indicators. In general, we focus on analyzing Vertex Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Vertex Pharmaceuticals's daily price indicators and compare them against related drivers.
| Downside Deviation | 1.39 | |||
| Information Ratio | 0.1903 | |||
| Maximum Drawdown | 6.68 | |||
| Value At Risk | (2.21) | |||
| Potential Upside | 3.06 |
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |